drugset / Trial / NCT00154427
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Africa, Asia, Europe, South America and the United States of America (USA). The trial is planned to investigate the safety and efficacy of NovoSeven® in the management of post-operative bleeding in patients following cardiac surgery.
Timeline
- Start
- 2004-08
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 40 ug/kg | — |
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 80 ug/kg | — |